

1.	<p>Treatment & Condition</p> <p>Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis</p>
2.	<p>Associated appraisal body & Summary of ruling</p> <p>Technology appraisal guidance [TA708] Published: 23 June 2021 https://www.nice.org.uk/guidance/TA708</p> <ul style="list-style-type: none"> • Budesonide as an orodispersible tablet (ODT) is recommended as an option for inducing remission of eosinophilic oesophagitis in adults. <p>This recommendation is not intended to affect treatment with budesonide ODT that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.</p>
3.	<p>Number of people in Northern Ireland expected to take up service/therapy</p> <p>According to the NICE Resource Impact Statement that accompanies NICE TA708, eosinophilic oesophagitis is a rare condition affecting around 13,000 people in England. By a pro rata calculation this equates to an estimated patient number in NI of 39 people.</p>
4.	<p>Patient Access Scheme Availability (Yes/No)</p> <p>Not applicable</p>
5.	<p>Infrastructure Requirements</p> <p>Any additional infrastructure costs associated will be dealt with as part of the routine commissioning process.</p>
6.	<p>Expected implementation period</p> <p>There is no impediment to immediate implementation for new patients.</p>
7.	<p>Commissioning arrangements</p> <p>Budesonide as an orodispersible tablet for this indication is commissioned by HSCB. Providers are HSC hospital trusts, and primary care.</p>
8.	<p>Monitoring arrangements</p> <p>Through usual monitoring of primary care drug budgets.</p>

9.

DoH (NI) Legislative/Policy Caveats

This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

The Rural Needs Act NI 2016 has been considered and this guidance, which is purely of a technical nature, is not regarded as falling within the scope of the act.